mascaretti srl facilities – analisibia.it
A buffered form of creatine does not promote greater changes in muscle creatine content, body composition, or training adaptations than creatine monohydrate.
Journal of the International Society of Sports Nutrition
Andrew R Jagim1, Jonathan M Oliver1,2, Adam Sanchez, Elfego Galvan, James Fluckey, Steven Riechman,
Michael Greenwood, Katherine Kelly, Cynthia Meininger, Christopher Rasmussen and Richard B Kreider.
Background: Creatine monohydrate (CrM) has been consistently reported to increase muscle creatine content and improve high-intensity exercise capacity. However, a number of different forms of creatine have been purported to be more efficacious than CrM. The purpose of this study was to determine if a buffered creatine monohydrate (KA) that has been purported to promote greater creatine retention and training adaptations with fewer side effects at lower doses is more efficacious than CrM supplementation in resistance-trained individuals.
Methods: In a double-blind manner, 36 resistance-trained participants (20.2 ± 2 years, 181 ± 7 cm, 82.1 ± 12 kg, and
14.7 ± 5% body fat) were randomly assigned to supplement their diet with CrM (CreapureW AlzChem AG, Trostberg, Germany) at normal loading (4 x 5 g/d for 7-days) and maintenance (5 g/d for 21-days) doses; KA (Kre-AlkalynW, All American Pharmaceutical, Billings, MT, USA) at manufacturer’s recommended doses (KA-L, 1.5 g/d for 28-days); or, KA with equivalent loading (4 x 5 g/d for 7-days) and maintenance (5 g/d) doses of CrM (KA-H). Participants were asked to maintain their current training programs and record all workouts.
Body water was estimated using an ImpediMed DF50 bioelectrical impedance analyzer (ImpediMed, San Diego, CA).Muscle biopsies from the vastus lateralis, fasting blood samples, body weight, DEXA determined body composition, and Wingate Anaerobic Capacity (WAC) tests were performed at 0, 7, and 28-days while 1RM strength tests were performed at 0 and 28-days. Data were
analyzed by a repeated measures multivariate analysis of variance (MANOVA) and are presented as mean ± SD changes from baseline after 7 and 28-days, respectively.
Impedimed, Hy-Dex ed il logo Impedimed sono marchi registrati di Impedimed Limited.
Ti potrebbero interessare anche i seguenti articoli: